Hexartan-MT 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 23.75 mg in an extended-release formulation. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. This combination is indicated for the management of hypertension, providing complementary mechanisms to achieve effective blood pressure control and reduce cardiovascular risk. The extended-release formulation ensures a sustained therapeutic effect, improving patient adherence by allowing once-daily dosing. Hexartan-MT 25 Tablet ER should be used with caution in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects may include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. This combination therapy offers a synergistic approach to hypertension management, optimizing efficacy while minimizing the potential for adverse effects associated with higher doses of individual agents.